OC-0079: Reproducibility of an NTCP model for tube-feeding dependence after H&N radiotherapy  by van der Schaaf, A. et al.
2nd ESTRO Forum 2013  S31 
	
OC-0079   
Reproducibility of an NTCP model for tube-feeding dependence 
after H&N radiotherapy 
A. van der Schaaf1, K. Wopken1, N.M. Sijtsema1, H.P. Bijl1, J.A. 
Langendijk1, A.A. van 't Veld1 
1University of Groningen University Medical Center Groningen, 
Radiation Oncology, Groningen, The Netherlands  
  
Purpose/Objective: NTCP models are known to be sensitive to 
variations in the dataset, leading to high model variability. We tested 
the reproducibility of a model that we developed for tube-feeding 
dependence using repeated data-resampling. 
Materials and Methods: A dataset of 416 patients that were treated 
with H&N radiotherapy in two hospitals was used to fit logistic 
models, using LASSO penalized learning, to predict tube feeding 
dependence at six month after treatment. We defined 21 candidate 
variables (see table), including 13 dosimetric variables. The LASSO 
method estimated the coefficients of the model, while restricting the 
coefficients to avoid overfitting. Variables with an estimated 
coefficient equal to zero were categorized as not selected. To test 
the reproducibility, we fitted 1000 models in a repeated 10-fold 
double cross-validation scheme. For each model a different selection 
of 80% of the original data was used. 
 
  
Results: The prediction performance of the models was good with an 
average area under the ROC curve of 0.85 in the independent 
validation sets. The variables 'Weight loss', 'Treatment modality', 
'Mean dose (MD) to the PCM superior (PCMsup)', and 'Tumor stage' (see 
table) were reproducibly identified in all models as strong risk factors. 
These variables together determine on average 87% of the variance of 
the linear part of the models. Five variables had a consistently low 
contribution to the models with selection frequencies below 10%. 
Eleven variables had an intermediate selection frequency between 
100% and 10%. The variable 'MD to the contralateral parotifd gland' 
(Pc) was selected often (98%), but with a notable negative correlation 
(-0.58) of the corresponding model coefficient with that of PCMsup 
(see figure). These two variables have the tendency to compete: when 
the coefficient of Pc increases the coefficient of PCMsup decreases in 
the model. This tendency is related to a strong correlation (0.79) of 
the data of these variables, and it signifies that the effect of both 
variables in the resulting models is difficult to distinguish from the 
available data. This behavior is also seen for the variables 'MD to the 
cricopharyngeus muscle 'and' MD to the esophageal inlet muscle', but 
much less for other variables, even though the average correlation of 
the data is relatively high (mean absolute value 0.34). The correlation 
between model coefficients is mostly close to zero (mean absolute 
value 0.14). 
 
 Conclusions: The method of repeated data-resampling enables the 
assessment of modeling reproducibility and variable competition. The 
NTCP model for tube feeding dependence is to a large extend 
reproducible. The four variables with the strongest association with 
the endpoint are modeled with a high degree of reproducibility, 
whereas the involvement of 11 variables with weaker associations 
remains uncertain in various degrees. 
 
OC-0080   
Treatment factors impacting on gastrointestinal toxicity following 
prostate radiotherapy 
M. Ebert1, M. Bulsara2, A. Haworth3, R. Kearvell4, A. Kennedy4, S. 
Richardson4, M. Krawiec4, N. Stewart4, D.J. Joseph4, J.W. Denham5 
1University of Western Australia, Academic Physics, Nedlands WA, 
Australia  
2University of Notre Dame, Biostatistics, Fremantle, Australia  
3Peter MacCallum Cancer Centre, Physical Sciences, Melbourne, 
Australia  
4Sir Charles Gairdner Hospital, Radiation Oncology, Perth, Australia  
5University of Newcastle, Medicine and Population Health, Newcastle, 
Australia  
 
Purpose/Objective: To assess the impact of treatment planning and 
delivery technique, as well as patient anatomical factors, on acute 
and late gastrointestinal toxicity using data from the TROG 03.04 
RADAR prostate radiotherapy trial. 
Materials and Methods: The RADAR trial accrued 813 external beam 
radiotherapy participants during 2003-2008. Following review and 
archive to a query-able database, digital treatment plans and data 
describing treatment technique for 754 patients were available. 
Anatomical features including organ volumes, extent and separations 
were automatically derived from the archived data and exported, 
together with treatment demographics and results of quality 
assessment against protocol requirements, for univariate and 
multivariate regression against toxicity scored using CTC v3.0 criteria 
and patient-reported quality of life questions at multiple timepoints. 
Regression analyses were reviewed in the context of dose-volume data 
for the rectum and anal canal. 
Results: With rectal dose-volume constraints applied in the RADAR 
protocol, toxicity rates have been found to be low. Univariate analysis 
revealed significant impact of multiple factors on acute and late 
toxicity, including – patient orientation (prone vs supine); the isodose 
encompassing the rectum; the number and energy of treatment 
beams; the number of accruals per contributing centre; the results of 
dosimetric audits; beam shaping method (blocks/collimators vs MLCs); 
and dose calculation algorithm. Prostate and rectum dimensions 
related relatively minimally to toxicity, as did dose conformation 
indices. Comparison with dose-volume information for the rectum 
shows that these associations often cannot be explained by variations 
in planned dose distribution and are likely due to subsequent 
unrecorded factors (such as setup and organ motion) and confounding 
associations inherent to the dataset. 
Conclusions: Significant interaction has been seen between treatment 
planning and delivery technique, the quality of radiotherapy 
planning/delivery and resulting gastrointestinal toxicity for prostate 
radiotherapy patients. These effects frequently cannot be explained 
by the underlying planned dosimetry.  
 
 
 
 
